Revefenacin

(Yupelri®)

Yupelri®

Drug updated on 11/15/2023

Dosage FormNebulizer (oral inhalation; 175 mcg/3mL)
Drug ClassAnticholinergics
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • To maintain treatment of chronic obstructive pulmonary disease.

Product Monograph / Prescribing Information

Document TitleYearSource
Yupelri (revefenacin) Prescribing Information.2022Mylan Specialty L.P., Morgantown, WV

Systematic Reviews / Meta-Analyses